Publications by authors named "Frederick Fasslrinner"

Claim this Profile
B
Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8 clonal effector and CAR T-cell function while promoting a senescence-associated phenotype.
Russell Towers, Lidia Trombello, Maximilian Fusenig, Antje Tunger, Anna-Lena Baumann, Frederick Fasslrinner

Cancer Immunol Immunother· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management.
Claudia Arndt, Ralf Bergmann, Franziska Striese, Keresztély Merkel, Domokos Máthé, Frederick Fasslrinner

Cancers (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR).
Nicola Mitwasi, Claudia Arndt, Liliana R Loureiro, Alexandra Kegler, Frederick Fasslrinner

Int J Mol Sci· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy.
Enrico Kittel-Boselli, Karla Elizabeth González Soto, Liliana Rodrigues Loureiro, Anja Hoffmann, Ralf Bergmann, Frederick Fasslrinner

Cancers (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis.
Alberto Farina, Federico Moro, Frederick Fasslrinner, Annahita Sedghi, Miluska Bromley

Pharmacol Res Perspect· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells.
Claudia Arndt, Liliana R Loureiro, Anja Feldmann, Justyna Jureczek, Ralf Bergmann, Frederick Fasslrinner

Oncoimmunology· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptor CAR Platforms-Next Generation of T Cell-Based Cancer Immunotherapy.
Claudia Arndt, Frederick Fasslrinner, Liliana R Loureiro, Stefanie Koristka, Anja Feldmann

Cancers (Basel)· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma.
Frederick Fasslrinner, Friedrich Stölzel, Michael Kramer, Raphael Teipel, Claudia Brogsitter

Biol Blood Marrow Transplant· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia.
Frederick Fasslrinner, Claudia Arndt, Stefanie Koristka, Anja Feldmann, Heidi Altmann

Br J Haematol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial.
Frederick Fasslrinner, Johannes Schetelig, Andreas Burchert, Michael Kramer, Rudolf Trenschel

Lancet Haematol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of mixed lymphocyte reaction supernatant on human mesenchymal stromal cells.
Frederick Fasslrinner, Manja Wobus, Regina Duryagina, Katrin Müller, Sabine Stopp

Exp Hematol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis